How does IDEXX's tax strategy affect bottom line?

IDEXXX's tax strategy does not appear to have a significant impact on its bottom line, based on the available data and information.

1. **Litigation Expense Accrual**: IDEXX has recorded a discrete litigation expense accrual in Q2, which affects its reported operating margins but does not necessarily impact its bottom line in a direct tax-related manner.
2. **Innovation and Growth Focus**: IDEXX's focus on innovation and expansion into new markets, such as the launch of the Cancer Dx panel, is more closely aligned with its growth strategy than a tax strategy. While effective tax management is important, there is no indication that IDEXX's tax strategy is a primary driver of its financial performance.

In conclusion, while tax management is crucial for any company, the available information suggests that IDEXX's tax strategy does not significantly affect its bottom line. Instead, its financial performance is more closely tied to its innovation, market expansion, and operational efficiency.